| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Alan J Russell is Chief Scientific Officer at EWTX. Alan J Russell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
Historically, Alan J Russell's trades have earned a strong insider score of 74/100 across 38 rated trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +20.8%.
The EWTX filings lean toward selling, a net 1,033,637 shares.
Alan J Russell has 30 Form 4 filings on record from August 2021 to August 2026, all as Chief Scientific Officer at Edgewise Therapeutics (EWTX), 2021–2026.
The 82 reported transactions were 54 open-market sales, 17 option exercises and 11 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 23 sales worth about $23.5M.
The largest open-market sale was 200,000 shares of EWTX at an average $39.41 on July 1, 2026, about $7.9M.
4 of the 13 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 9 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 5,901 | $43.73 | $258,042.47 | -15.8% | - | - | |
| Jul 1, 2026 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 200,000 | $39.41 | $7,881,401.98 | -89.1% | +0.1% | - | |
| Nov 12, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 100,000 | $21.12 | $2,112,450.00 | -81.0% | +46.4% | - | |
| Aug 26, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 100,000 | $14.60 | $1,459,760.00 | -81.0% | +60.8% | +204.0% | |
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 1,907 | $13.39 | $25,539.31 | -7.5% | +36.5% | +225.3% | |
| May 2, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 1,551 | $16.45 | $25,520.46 | -7.7% | -15.7% | +81.0% | |
| Mar 7, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 200 | $30.02 | $6,004.00 | -1.3% | -47.1% | -0.7% | |
| Feb 6, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 9,215 | $30.04 | $276,776.12 | -38.3% | -49.4% | +1.4% | |
| Dec 30, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 100,000 | $27.37 | $2,737,470.00 | -87.1% | -18.7% | -9.3% | |
| Sep 20, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 75,000 | $28.27 | $2,120,101.20 | -85.5% | +8.9% | -49.6% |